8th
Urologic Oncology:Advances in Clinical Practice
November 8–9, 2013
MD Anderson Dan L. Duncan BuildingConference Center, Floor 8 1155 PresslerHouston, Texas
FocusThe 8th Urologic Oncology Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced bladder, prostate, kidney, penile and testis cancers.
Educational ObjectivesAfter attending the conference, participants should be able to• Implementandillustrateclinicaladvancesinthediagnosisandevaluation
ofbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence, Performance, Patient Outcomes);
• Implementandillustrateclinicaladvancesinthetreatmentapproachtolocalizedandlocallyadvancedbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence, Performance, Patient Outcomes);
• Implementandillustrateclinicaladvancesinthetreatmentapproachtometastaticbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence, Performance, Patient Outcomes);
• Identifyandaccesscontemporarycontroversiesinthemanagementofbladder,prostate,kidney,penileandtestiscancers(Knowledge, Competence).
Educational MethodsLectures – Case Presentations – Panel Discussions – Audience Response System – Question and Discussion Sessions
8th Urologic Oncology: Advances in Clinical PracticeNovember 8-9, 2013
Target AudienceThis conference should be of value to urologists, medical oncologists, nurses, nurse practitioners, and physician assistants.
EvaluationAcourseevaluationformwillprovideparticipantswiththeopportunitytocommentonthevalueoftheprogramcontenttotheirpracticedecisions,performanceimprovementactivities,orpossibleimpactonpatienthealthstatus.Participantswillalsohavetheopportunitytocommentonanyperceivedcommercialbiasinthepresentationsaswellastoidentifyfutureeducationaltopics.
Accreditation/Credit DesignationPhysiciansTheUniversityofTexasMDAndersonCancerCenterisaccreditedbytheAccreditationCouncilforContinuingMedicalEducationtoprovidecontinuingmedicaleducationforphysicians.
TheUniversityofTexasMDAndersonCancerCenterdesignatesthisliveactivityforamaximumof15.75AMA PRA Category 1 Credits TM.Physiciansshouldclaimonlythecreditcommensuratewiththeextentoftheirparticipationintheactivity.
CME Certificates and Attendance Verification CertificatesCertificatesawardingAMA PRA Category 1 Credit TMorcertificatesdocumentingattendancewillbedistributedtoparticipantsastheydepartthesymposium.ToobtainaCMEcertificate,physiciansmustsubmitacompletedevaluationquestionnaireandaCMEVerificationForm.
Uponrequest,arecordofattendance(certificate)willbeprovidedon-sitetootherhealthcareprofessionalsforrequestingcreditsinaccordancewithstatenursingboards,specialtysocieties,orotherprofessionalassociations.
Christopher G. Wood, MDProgram Co-ChairmanProfessor and Vice ChairmanUrology
Nizar M. Tannir, MDProgram Co-ChairmanAssociate Professor and Vice ChairmanGenitourinary Medical Oncology
Ana Aparicio, MDAssistant ProfessorGenitourinary Medical Oncology
Brian F. Chapin, MDAssistant ProfessorUrology
John W. Davis, MDAssociate ProfessorUrology
Colin P. Dinney, MDProfessor and ChairmanUrology
Jay B. Shah, MDAssistant ProfessorUrology
Arlene Siefker-Radtke, MDAssociate ProfessorGenitourinary Medical Oncology
Gloria CurtisSr. Administrative AssistantGenitourinary Medical Oncology
Carol FourtuniaSr. Administrative AssistantUrology
Constance C. Tierney, CMPManagerCME/Conference Management
Conference Chairmen
Conference Committee
MDAndersonOrganizingCommittee
Friday,November8,20137:00a.m. RegistrationandContinentalBreakfast
7:50 Welcome and Opening Remarks ChristopherG.Wood,MDandNizarM.Tannir,MD
SeSSion i: PeniLe/TeSTiS CAnCeR Moderator: Louis L. Pisters, MD
8:00 Update on Surgical Options for Localized and Locally Advanced Penile Cancer
CurtisA.Pettaway,MD 8:20 Update on Chemotherapy Options for Locally Advanced and Metastatic Penile Cancer LanceC.Pagliaro,MD
8:40 Distinguished Alumnus Presentation Topical Therapy for Non-Muscle Invasive Urothelial Carcinoma:
Past, Present & Future WadeJ.Sexton,MD
9:00 Management of High Risk Stage I Testis Cancer
Case Presentation22yearoldWMpresentswithrighttesticularmass.Metastaticevaluationnegative.AFP90ng/ml,b-HCG<1.0mlU/ml.Undergoesrightradicalorchiectomy.Pathology70%embryonal,25%teratoma,5%seminoma.Invasionintotheretetestis.+LVI.Markersnormalizeappropriatelyaftersurgery.
Observation JoseA.Karam,MD
Chemotherapy JenniferWang,MD
RPLND JohnF.Ward,MD
9:45 Risk Adapted Management of Patients With Advanced Poor-Risk NSGCT LanceC.Pagliaro,MD
ProgramUrologic oncology: Advances in Clinical Practice
10:00 Management of Patients With Platinum Refractory Advanced Germ
Cell Tumors: Role of High-Dose Chemotherapy and Stem Cell Transplantation
YagoNieto,MD 10:15 Questions and Discussion
10:25 Break
10:40 Outcomes and Complications of Post-Chemotherapy RPLND for Metastatic Testis Cancer
LouisL.Pisters,MD 10:55 Management of the Residual Mass in Metastatic Seminoma
s/p Chemotherapy Shi-MingTu,MD
11:10 Case Presentations Moderators: Curtis A. Pettaway, MD and Louis L. Pisters, MD Panelists:JoseA.Karam,MD;YagoNieto,MD;LanceL.Pagliaro,MD;
WadeJ.Sexton,MD;Shi-MingTu,MD;JohnF.Ward,MD
Noon Lunch(Provided)
SeSSion ii: URoTHeLiAL CAnCeR Superficial Bladder CancerModerator: Jay B. Shah, MD
1:00p.m. Novel Approaches to Localized Bladder Cancer ColinP.Dinney,MD
1:10 Controversy: Recurrent T1HG After Induction BCG
Continued Intravesical Therapy is Best ColinP.Dinney,MD
Immediate Cystectomy is Best AshishKamat,MD
Chemoradiation is Best KarenHoffman,MD
Upper Tract DiseaseModerator: Jay B. Shah, MD
1:40 Treatment of Superficial Upper Tract Transitional Cell Carcinoma SurenaF.Matin,MD
1:50 Controversy: HG Tumor of Left Distal Ureter Immediate Distal Ureterectomy is Best NeemaNavai,MD
Neoadjuvant Chemotherapy is Best ArleneSiefker-Radtke,MD
2:00 Questions and Discussion Case Presentations Moderator: Jay B. Shah, MD Panelists:ColinP.Dinney,MD;KarenHoffman,MD;AshishKamat,MD; SurenaF.Matin,MD;NeemaNavai,MD;WadeJ.Sexton,MD; ArleneSiefker-Radtke,MD
2:40 Break
invasive Urothelial CancerModerator: Arlene Siefker-Radtke, MD3:00 Controversy: 63 Year Old Man With T2 Bladder Cancer Open Cystectomy is the Best Option AshishKamat,MD
Robotic Cystectomy is the Best Option JayB.Shah,MD
3:20 Controversy: 63 Year Old Man Undergoing Cystectomy Needs Urinary Diversion Orthotopic Neobladder is Best Choice H.BartonGrossman,MD
Continent Cutaneous Diversion is Best Choice O.LenaineWestney,MD
Ileal Conduit is Best Choice JayB.Shah,MD
3:50 Controversy: 63 Year Old Man With T3 Bladder Cancer Wants Neoadjuvant Chemo MVAC is Best Choice JianjunGao,MD,PhD
Gem/Cis is Best ArleneSiefker-Radtke,MD
4:10 Novel Chemo Situations and Novel Chemo Options ArleneSiefker-Radtke,MD
4:20 Questions and Discussion Case Presentations Moderator: Arlene Siefker-Radtke, MD Panelists:JianjunGao,MD,PhD;H.BartonGrossman,MD;
AshishKamat,MD;JayB.Shah,MD;O.LenaineWestney,MD
5:00 Break
5:15 Andrew C. von Eschenbach Lecture Maximizing Perioperative Management of the IVC for Tumor
Thrombectomy Improves Safety of Radical Nephrectomy MichaelBlute,Sr.,MD
6:00 Reception
Saturday,November9,20137:00a.m. RegistrationandContinentalBreakfast
SeSSion iii: RenAL CAnCeR Moderator: Christopher G. Wood, MD
8:00 Management of Small Renal Mass Debate
Case Presentation70yearoldWMwith3.0cmenhancingrenalmass.PMHsignificantforHtn,CAD,DM
What is the Best Treatment Option? SRM: Active Surveillance SurenaF.Matin,MD
SRM: Intervention JoseA.Karam,MD
8:30 Role of Lymph Node Dissection in Locally Advanced Renal Cell Carcinoma Debate
Case Presentation55yearoldWMwithcT3brightrenaltumor.Noevidenceofmetastaticdisease. Lymph Node Dissection: Pro ChristopherG.Wood,MD
Lymph Node Dissection: Con BrianF.Chapin,MD
9:00 Timing of Cytoreductive Surgery in Metastatic Renal Cell Carcinoma Debate
Case Presentation65yearoldWFpresentswithlocallyadvancedrenalprimarytumorandpulmonarymets.PS1.Nocomorbidconditions. Upfront Cytoreductive Nephrectomy NizarM.Tannir,MD Delayed Cytoreductive Nephrectomy EricJonasch,MD
9:30 What is the Most Appropriate Front Line Therapy for Metastatic Renal Cell Carcinoma Debate
Case Presentation53yearoldWMs/pcytoreductivenephrectomyforaT3aN0M1ccRCC.PS0.LabsWNLexceptHb10.3.Bilateralpulmonarymetastases. First Line Therapy: TKI MarthaP.Mims,MD,PhD First Line therapy: Immunotherapy NizarM.Tannir,MD
10:00 Questions and Discussion
10:10 Break
10:30 Case Presentations Moderator: Christopher G. Wood, MD Panelists:MichaelBlute,Sr.,MD;BrianF.Chapin,MD;EricJonasch,MD;
JoseA.Karam,MD;SurenaF.Matin,MD;MarthaP.Mims,MD,PhD;WadeJ.Sexton,MD;NizarM.Tannir,MD
Noon Lunch(provided)
SeSSion iV: PRoSTATe CAnCeR Radical ProstatectomyModerator: John W. Davis, MD
1:00p.m. How To Improve Urinary and Sexual Function Outcomes SurenaF.Matin,MD
1:15 Discussion/Critique JohnF.Ward,MD;LouisL.Pisters,MD;CurtisA.Pettaway,MD
1:25 How and When to Extend the Pelvic Lymph Node Dissection? BrianF.Chapin,MD
1:40 Discussion/Critique StevenE.Canfield,MD
Health Services Debate: Robot-Assisted Radical Prostatectomy is a Good Investment1:45 Pro JayB.Shah,MD
1:55 Con KarenHoffman,MD
Radiation oncology UpdatesModerator: Deborah A. Kuban, MD
Technique Debate: Best Radiation Therapy for Localized Prostate Cancer2:10 Proton SeungtaekChoi,MD
2:20 IMRT UsamaMahmood,MD
2:30 Brachytherapy StevenJ.Frank,MD
2:40 Discussion/Critique AnaAparicio,MD;WilliamJ.Graber,MD;JohnN.Papadopoulos,MD
3:00 Break
Endocrinology and Systemic Therapy UpdatesModerator: Christopher J. Logothetis, MD
3:15 Testosterone Replacement After Radical Prostatectomy MohitKhera,MD
3:30 Zoledronic Acide vs. Denosumab for Metastatic Prostate Cancer EmilyWang,PharmD
3:45 The Future is Now: Systemic Agents Will Help the Urologist Cure the Uncurrable JohnW.Davis,MD;ChristopherJ.Logothetis,MD
4:00 Discussion/Critique MohitKhera,MD;EmilyWang,PharmD;JohnW.Davis,MD; ChristopherJ.Logothetis,MD
MD Anderson Faculty
Ana Aparicio, MDAssistant ProfessorGenitourinary Medical Oncology
Brian F. Chapin, MDAssistant ProfessorUrology
Seungtaek Choi, MDAssistant ProfessorRadiation Oncology
John W. Davis, MDAssociate ProfessorUrology
Colin P. Dinney, MDChairman & ProfessorUrology
Steven J. Frank, MDAssociate ProfessorRadiation Oncology
Jianjun Gao, MD, PhDAssistant ProfessorGenitourinary Medical Oncology
William J. Graber, MDAssociate ProfessorUrology
H. Barton Grossman, MDClinical ProfessorUrology
Karen Hoffman, MDAssistant ProfessorRadiation Oncology
Eric Jonasch, MDAssociate ProfessorGenitourinary Medical Oncology
Ashish Kamat, MDAssociate ProfessorUrology
Jose A. Karam, MDAssistant ProfessorUrology
Deborah A. Kuban, MDProfessorRadiation Oncology
Christopher J. Logothetis, MDChairman & ProfessorGenitourinary Medical Oncology
Usama Mahmood, MDAssistant ProfessorRadiation Oncology
Case Presentations Moderators: John W. Davis, MD and Ana Aparicio, MDPanelists:BrianF.Chapin,MD;StevenJ.Frank,MD;DeborahA.Kuban,MD;ChristopherJ.Logothetis,MD;JohnF.Ward,MD
4:20 Topics:SequencingandCombiningNovelSystemicAgentsPredictingFailureAfterLocalTherapy.WillNovelRiskClassifiersHelpUs?ImagingChallenges
5:00 Adjourn
Surena F. Matin, MDAssociate ProfessorUrology
Neema Navai, MDAssistant ProfessorUrology
Yago Nieto, MDProfessorStem Cell Transplantation
Lance C. Pagliaro, MDProfessorGenitourinary Medical Oncology
John N. Papadopoulos, MDAssistant ProfessorUrology
Curtis A. Pettaway, MDProfessorUrology
Louis L. Pisters, MDProfessorUrology
Jay B. Shah, MDAssistant ProfessorUrology
Andrew C. von Eschenbach LectureMichael Blute, Sr., MDChief of Urology, Massachusetts General HospitalProfessor of Urology, Harvard Medical SchoolBoston, Massachusetts
Distinguished AlumniWade J. Sexton, MDAssociate Professor University of South FloridaDepartment of Genitourinary OncologyDirector, Urologic Oncology Fellowship ProgramMoffitt Cancer CenterTampa, Florida
Guest FacultySteven E. Canfield, MDAssociate ProfessorDivision of Urology/Department of SurgeryUT Health Science CenterHouston, Texas
Mohit Khera, MDAssistant ProfessorScott Department of Urology/Baylor ClinicBaylor College of MedicineHouston, Texas
Martha P. Mims, MD, PhDAssociate ProfessorDepartment of Hematology & OncologyBaylor College of MedicineHouston, Texas
Arlene Siefker-Radtke, MDAssociate ProfessorGenitourinary Medical Oncology
Nizar M. Tannir, MD Associate Professor & Vice ChairmanGenitourinary Medical Oncology
Shi-Ming Tu, MDProfessorGenitourinary Medical Oncology
Emily Wang, PharmDClinical Pharmacy SpecialistPharmacy
Jennifer Wang, MDAssistant ProfessorGenitourinary Medical Oncology
John F. Ward, MDAssociate ProfessorUrology
O. Lenaine Westney, MDAssociate ProfessorUrology
Christopher G. Wood, MDProfessor & Vice ChairmanUrology
Urologic oncology: Advances in Clinical PracticeOn-siteregistrationopensat7:00a.m.onFriday, November 8, 2013.Theconferencewillbeginat7:50amonFriday, November 8, 2013 andadjournonSaturday,November9,2013at5:00p.m.Advanceregistrationisencouragedasspaceandmaterialsarelimited.Pleaseseetheregistrationformforapplicablefees.
Thefullconferenceregistrationfeeincludesthetuition,syllabus,breakfasts,breaks,lunches,andreception.
The deadline for advance registration is Friday, October 18, 2013.
There are three ways to register:•Mailto:CME/ConferenceManagement–Unit1381,TheUniversityofTexas
MDAndersonCancerCenter,P.O.Box301439,Houston,TX77230-1439•Faxto:713-794-1724•On-lineatwww.mdanderson.org/conferences
We accept the following forms of payment:•Check(payablethroughU.S.banksonly)•MoneyOrder•CreditCards(MasterCard,VISA,andAmericanExpress)•Cash(on-siteregistrationonly)
Whenregisteringonlineareceipt/confirmationletterwillbeautomaticallye-mailedtothee-mailaddressyoulistontheregistrationform.Ifyouregisterbyfaxormail,areceipt/confirmationletterwillbesenttoyouwithintenworkingdaysofreceiptofyourfee.
Registration Information
Refund/CancellationPolicy Theregistrationfee,minusa$50administrativehandlingfee,isrefundableifawrittenrequestisreceivedonorbeforeOctober18,2013.Norefundswillbegrantedafterthatdate.Therequestforaregistrationrefundmustincludethetaxidentificationnumberofthecompanyorinstitutionifregistrationwaspaidbyacompanyorinstitutioncheck.
TheDepartmentofCME/ConferenceManagementreservestherighttocancelactivitiespriortothescheduleddate,iflowenrollmentorothercircumstancesmakeitnecessary.Eachregistrantwillbenotifiedbymail,e-mail,oratthephoneorfaxnumbersgivenontheregistrationform.Incaseofactivitycancellation,theliabilityoftheDepartmentofCME/ConferenceManagementislimitedtotheregistrationfee.CME/ConferenceManagementwillrefundthefullregistrationfee.
TheDepartmentofCME/ConferenceManagementreservestherighttolimitthenumberofparticipantsinaprogramandisnotresponsibleforanyexpensesincurredbyanindividualwhoseregistrationisnotconfirmedandforwhomspaceisnotavailable.
SpecialAssistanceContacttheDepartmentofCME/ConferenceManagementat713-792-2223ortollfreeat866-849-5866ifyouhaveanyspecialdietaryorADAaccommodationneeds.
Accommodations• Ablockofroomshasbeenreservedforconferenceattendeesatthe Houston Marriott at the Texas Medical Center,6580FanninStreet,Houston,Texas.• Earlyhotelreservationissuggested.Tomakereservations,pleasecallMarriott
Reservationsat800-228-9290andidentifyyourselfaspartoftheMDAndersonUrologicOncologyConference
• Thespecialmeetingrateis$114.00singleordoubleoccupancy.Pleaseadd17% TexasStateandlocaltaxes.ReservationsanddepositsreceivedafterOctober17, 2013willbeconfirmedifspaceisavailableandatcurrenthotelpublishedguest
roomrates.
Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.
GroundTransportation (prices are subject to change and variable depending on location of conference)• Houstonisservedbytwoairports,GeorgeBushIntercontinental(IAH)and
WilliamP.Hobby(HOU).
• Taxicabsareavailableatanestimatedcostfor$50-60,toorfromWilliamP.HobbyAirportorGeorgeBushIntercontinentalAirport.
• SuperShuttleoperatesashuttlebusbetweenGeorgeBushIntercontinentalAirportandtheHoustonMarriottattheTexasMedicalCenterfor$27one-wayand$54round-trip.Formoreinformation,call713-523-8888ortoll-freeat800-258-3826oron-lineatwww.supershuttle.com.
• SuperShuttleoperatesashuttlebusbetweenWilliamP.HobbyAirportandtheHoustonMarriottattheTexasMedicalCenterfor$24one-wayand$48round-trip.Formoreinformation,call713-523-8888ortoll-freeat800-258-3826oron-lineatwww.supershuttle.com.
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.
Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable exper-tise on rare occasions necessitated by illness, schedule conflicts, and so forth.
Photographing, audio taping and videotaping are prohibited.
CON
FERE
NCE
REG
ISTR
ATIO
N -
PS10
0595
/111
409
8th
Urol
ogic
Onco
logy
: Ad
vanc
es in
Clin
ical P
ract
ice —
Nov
embe
r 8-9
, 201
3
THIS
IS N
OT A
SEL
F-M
AILE
R - A
ddre
ss to
: 8t
h Ur
olog
ic O
ncol
ogy:
Adv
ance
s in
Clin
ical
Pra
ctic
eN
ovem
ber 8
-9, 2
013
Depa
rtmen
t of C
ME/
Conf
eren
ce M
anag
emen
t Un
it 13
81Th
e Un
iver
sity
of T
exas
MD
Ande
rson
Can
cer C
ente
r PO
Box
301
439,
Hou
ston
, TX
7723
0-14
39or
fax
to 7
13-7
94-1
724
Mak
e ch
eck
or m
oney
ord
er p
ayab
le to
: Th
e Un
iver
sity
of T
exas
MD
Ande
rson
Can
cer C
ente
r
GENE
RAL C
ONFE
RENC
E RE
GIST
RATI
ON FE
ESPh
ysic
ians
1 P
ostm
arke
d on
or b
efor
e Oc
t. 18
, 201
3 .....
.$25
0.00
1 P
ostm
arke
d af
ter O
ct. 1
8, 20
13 ...
........
........
$300
.00
Stud
ents
/ Tr
aine
es /
PAs /
Ad
vanc
ed N
urse
Pra
ctiti
oner
s1 P
ostm
arke
d on
or b
efor
e Oc
t. 18
, 201
3 .....
.$55
.00
1 P
ostm
arke
d af
ter O
ct. 1
8, 20
13 ...
........
........
$80.0
0
Last
Nam
e
Fi
rst
M
I
H
ighe
st D
egre
e
Depa
rtmen
t (in
clud
e bo
x no
.)
Sp
ecia
lty
Inst
itutio
n
Ph
ysic
ian
Stre
et
City
S
tate
/For
eign
Cou
ntry
/Zip
or M
ail C
ode
Dayt
ime
Phon
e (w
ith a
rea
code
)
Cel
l Pho
ne (w
ith a
rea
code
)
F
ax (w
ith a
rea
code
)
E-m
ail A
ddre
ss
Emer
genc
y Co
ntac
t
Pho
ne (w
ith a
rea
code
)
Char
ge th
e fo
llow
ing:
o
VISA
oM
aste
rCar
d
o
Amer
ican
Exp
ress
Cred
it Ca
rd N
umbe
r
Exp
iratio
n Da
te
Busi
ness
Uni
t D
epar
tmen
t
Fun
d Gr
oup
F
und
F
und
Type
PC
By
Pr
ojec
t
Ac
tivity
Cred
it Ca
rd H
olde
r Nam
e (F
irst/
Last
)
Cre
dit C
ard
Hold
er B
illin
g Ad
dres
s &
ZIP
Cod
e
Auth
orize
d Si
gnat
ure
REQU
IRED
for c
redi
t car
d or
IDT
MD
Ande
rson
Em
ploy
ee ID
No.
(REQ
UIRE
D)
IDT
Appr
over
Nam
e (F
irst/
Last
) ple
ase
prin
t
I
DT A
ppro
ver E
-mai
l
oYe
s
o
No
MD
And
erso
n In
terd
epar
tmen
tal T
rans
fer (
IDT)
No.
:
Depa
rtmen
t of C
ME/
Conf
eren
ce M
anag
emen
t - U
nit 1
381
The
Univ
ersi
ty o
f Tex
as M
D An
ders
on C
ance
r Cen
ter
#176
700/
1114
09/ P
S100
595
PO B
ox 3
0143
9Ho
usto
n, T
X 77
230-
1439
Non
-Pro
fit O
rg.
U.S.
Pos
tage
PAID
Perm
it N
o. 7
052
Hous
ton,
TX
Top Related